Update on Real-World Experience With HARVONI

Size: px
Start display at page:

Download "Update on Real-World Experience With HARVONI"

Transcription

1 Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data were derived from patient medical records and specialty pharmacy databases. Such data are retrospective and observational in nature, and are not based on controlled clinical studies. Results from these cohorts may differ from results seen in the membership of a particular payer. INDICATIONS AND USAGE Harvoni is indicated with or without ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection.

2 1 TABLET ONCE A DAY Pill not actual size Ledipasvir (9 mg) An HCV NS5A inhibitor Sofosbuvir (4 mg) A nucleotide analog inhibitor of HCV NS5B polymerase is indicated with or without ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection. Contraindications If is used in combination with ribavirin (RBV), all contraindications, warnings and precautions, in particular pregnancy avoidance, and adverse reactions to RBV also apply. Refer to RBV prescribing information. 1

3 RECOMMENDED TREATMENT DURATION FOR HCV GT 1, 4, 5, OR 6 PATIENTS, INCLUDING THOSE WITH HCV/HIV-1 COINFECTION 1 1 TABLET DAILY 8 WEEKS Can be considered in treatment-naïve (TN) GT 1 patients without cirrhosis and with pre-treatment HCV RNA <6 million IU/mL 12 WEEKS TN GT 1 patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) Treatment-experienced (TE) a GT 1 patients without cirrhosis TN or TE a GT 4, GT 5 or GT 6 patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) NO FOOD REQUIREMENT + RBV 12 WEEKS TN and TE a GT 1 patients with decompensated cirrhosis (Child-Pugh B or C) b TN and TE a GT 1 or GT 4 liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh A) c 24 WEEKS TE a GT 1 patients with compensated cirrhosis (Child- Pugh A) d a TE patients include those who have failed a peginterferon alfa + ribavirin (RBV)-based regimen with or without an HCV protease inhibitor. b In patients with decompensated cirrhosis (Child-Pugh B or C), the starting dosage of RBV is 6 mg and can be titrated up to 1 mg for patients <75 kg and 12 mg for those 75 kg in two divided doses with food. If the starting dosage of RBV is not well tolerated, the dosage should be reduced as clinically indicated based on hemoglobin levels. c The daily dosage of RBV is weight-based (1 mg for patients <75 kg and 12 mg for those 75 kg) administered orally in two divided doses with food. Refer to the RBV prescribing information. d + RBV for 12 weeks can be considered in TE GT 1 patients with cirrhosis who are eligible for RBV. See footnote c for RBV dosage recommendations. For patients with HCV/HIV-1 coinfection, refer to the Drug Interactions section of the Prescribing Information for dosage recommendations for concomitant HIV-1 antiretroviral drugs No dose recommendation can be given for patients with severe renal impairment (estimated Glomerular Filtration Rate [egfr] <3 ml/min/1.73m 2 ) or with end-stage renal disease (ESRD) due to higher exposures (up to 2-fold) of the predominant sofosbuvir metabolite Warnings and Precautions Risk of Serious Symptomatic Bradycardia When Coadministered with Amiodarone: Amiodarone is not recommended for use with due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease. In patients without alternative, viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia. 2

4 CLINICAL STUDIES IN PATIENTS WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A) 1 Study Weeks ION-1 and ION-2 ION-3 ION-4 SIRIUS + RBV a + RBV a Primary endpoint: sustained virologic response (SVR12), defined as HCV RNA <25 IU/mL at 12 weeks after the cessation of treatment 1, b SVR12 is considered a virologic cure 2 + RBV a Baseline demographics ION-1 1 ION-2 1 ION-3 1 ION-4 1,3 SIRIUS 1 N Design Randomized, open-label Randomized, open-label Randomized, open-label Single-arm, open-label Randomized, placebo-controlled c Cirrhotics 16% (n = 136) 2% (n = 88) None 2% (n = 67) 1% (n = 155) Prior treatment TN Peg-IFNa + RBV or Peg-IFNa + RBV + HCV PI TN TN or RBV +/- PegIFN +/- HCV DAA Peg-IFNa + RBV followed by Peg-IFNa + RBV + HCV PI HCV GT GT 1 GT 1 GT 1 GT 1 or GT 4 d GT 1 HCV/HIV-1 coinfection No No No Yes No DAA = direct-acting antiviral agent; Peg-IFNa = peginterferon alfa. a RBV 1-12 mg/day. b Relapse was a secondary endpoint. c In the 12-week arm, subjects received placebo for 12 weeks followed by + RBV for 12 weeks. d GT 1, n = 327; GT 4, n = 8. Warnings and Precautions (cont.) Risk of Reduced Therapeutic Effect of Due to P-gp Inducers: Rifampin and St. John s wort are not recommended for use with as they may significantly decrease ledipasvir and sofosbuvir plasma concentrations. Related Products Not Recommended: is not recommended for use with other products containing sofosbuvir. 3

5 CLINICAL STUDIES IN PATIENTS WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A) 1 (cont.) Patients achieving SVR12 with ± RBV Patients (%) % 96% 99% 96% 95% 96% 97% 1% 8 Weeks + RBV 24 Weeks 2 n = 215 n = 216 n = 214 n = 335 n = 87 n = 77 n = 77 n = 22 ION-3 a ION-3 ION-1 ION-4 b ION-2 SIRIUS SIRIUS ION-2 TN, NC TN, NC/CC TN/TE, NC/CC TE, NC TE, CC CC = compensated cirrhosis (Child-Pugh A); NC = noncirrhotic. Adverse reactions (all grades) reported in 5% of GT 1 patients receiving for 8, 12, or 24 weeks: ION-1, ION-2, and ION-3 8 Weeks (N = 215) (N = 539) 24 Weeks (N = 326) Fatigue 16% 13% 18% Headache 11% 14% 17% Nausea 6% 7% 9% Diarrhea 4% 3% 7% Insomnia 3% 5% 6% The safety profile in HCV/HIV-1 coinfected subjects (ION-4) was similar to that observed in HCV monoinfected subjects The most common adverse reactions occurring in at least 1% of subjects were headache (2%) and fatigue (17%) Direct comparisons across studies should not be made due to differing study designs Adverse reactions reported in 5% of TE, CC, GT 1 patients receiving for 24 weeks or + RBV for 12 weeks versus placebo: SIRIUS 24 Weeks (N = 78) + RBV (N = 76) Placebo (N = 77) Asthenia 31% 36% 23% Headache 29% 13% 16% Fatigue 18% 4% 1% Cough 5% 11% 1% Myalgia 9% 4% Dyspnea 3% 9% 1% Irritability 8% 7% 1% Dizziness 5% 1% Footnotes for all figures: a Subgroup of TN, NC, GT 1 HCV patients with baseline HCV RNA <6 million IU/mL. In ION-3, relapse rates for for 8 weeks were 2% (n = 2/123) in patients with baseline HCV RNA <6 million IU/mL and 1% (n = 9/92) in patients with baseline HCV RNA 6 million IU/mL. b Patients with GT 1 or 4 HCV with HIV coinfection. Adverse Reactions Most common ( 1%, all grades) adverse reactions were fatigue, headache and asthenia. 4

6 REAL-WORLD EXPERIENCE: HCV-TARGET 4 Baseline demographics 8 Weeks (N = 154) (N = 627) 24 Weeks (N = 161) Male, n (%) 7 (46) 367 (59) 12 (63) Median age, years (range) 58 (19-84) 6 (21-87) 6 (3-8) White, n (%) 116 (75) 441 (7) 131 (81) Black, n (%) 34 (22) 136 (22) 22 (14) Prior HCV treatment, n (%) Experienced DAA experienced HCV genotype, n (%) 1a 1b 6 (4) 2 (1) 11 (66) 45 (29) 252 (4) 63 (1) 46 (65) 176 (28) 156 (97) 51 (32) 11 (68) 33 (21) Cirrhosis, n (%) 3 (2) 183 (29) 126 (78) Mean HCV RNA (log 1 ) HIV, n (%) 1 (1) 19 (3) 5 (3) PPI use, n (%) 3 (2) 163 (26) 54 (34) DAA = direct-acting antiviral; PPI = proton pump inhibitor. HCV-TARGET is a consortium of healthcare providers from academic (n = 44) and community (n = 17) medical centers in the United States (US) (primarily) and Europe conducting a longitudinal, observational study of HCV management in clinical practice All data throughout treatment and during posttreatment follow-up were collected from medical records and entered into a centralized database Data were independently reviewed for completeness and accuracy HCV treatment regimen was selected and administered at clinicians discretion according to local standards of care Patients in this analysis completed treatment before July 1, 215 Patients achieving SVR12 with Patients (%) % 97% 95% n = 127/131 n = 67/627 n = 153/161 8 a Treatment Duration (Weeks) a Subgroup of patients treated with 8 weeks according to label (ie, GT 1 TN, noncirrhotic, pretreatment HCV RNA <6 million IU/mL). Treatment with for 8, 12, or 24 weeks resulted in SVR12 rates of 95% Across all treatment arms: 2% of patients discontinued treatment (n = 31) 1% (n = 17) were lost to follow-up posttreatment.5% (n = 11) died for 12 weeks is recommended for TN GT 1 patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) and for TE GT 1 patients without cirrhosis. for 8 weeks can be considered in TN GT 1 patients without cirrhosis who have pre-treatment HCV RNA <6 million IU/mL. for 24 weeks is recommended for TE GT 1 patients with compensated cirrhosis (Child-Pugh A). + RBV for 12 weeks can be considered in TE GT 1 patients with compensated cirrhosis (Child-Pugh A) who are eligible for RBV. 1 Drug Interactions In addition to rifampin and St. John s wort, coadministration of is also not recommended with carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifapentine, and tipranavir/ritonavir. Such coadministration is expected to decrease the concentration of ledipasvir and sofosbuvir, reducing the therapeutic effect of. 5

7 REAL-WORLD EXPERIENCE: HCV-TARGET 4 (cont.) The overall SVR12 rate with treatment was 97% Patients achieving SVR12 with a % 98% 93% b 96% 98% Patients (%) Overall Yes Cirrhosis No Naïve Experienced Prior Treatment a For 8 (n = 154), 12 (n = 627), or 24 (n = 161) weeks. b P<.5. Adverse events reported in 5% of patients receiving in HCV-TARGET 4 (n = 1435) 4 (n = 1435) Any adverse event, n (%) 9 (63) Insomnia 89 (6) Fatigue 32 (22) Diarrhea 86 (6) Headache 37 (21) Influenza-like illness 65 (5) Nausea 19 (8) Across the ION-1, ION-2, and ION-3 clinical trials, adverse reactions (all grades) reported in 5% of subjects receiving 8, 12, or 24 weeks of treatment with were fatigue (13%-18%), headache (11% 17%), nausea (6%-9%), diarrhea (3%-7%), and insomnia (3%-6%) 1 Patients who may be considered for 8 weeks of are those with GT 1 HCV who are treatment-naïve without cirrhosis and have a baseline HCV RNA <6 million IU/mL. In ION-3, relapse rates for for 8 weeks were 2% (n = 2/123). in patients with baseline HCV RNA <6 million IU/mL and 1% (n = 9/92) in patients with baseline HCV RNA 6 million IU/mL. 1 Drug Interactions (cont.) Coadministration of is not recommended with simeprevir due to increased concentrations of ledipasvir and simeprevir. Coadministration is also not recommended with rosuvastatin or co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate due to increased concentrations of rosuvastatin and tenofovir, respectively. Consult the full Prescribing Information for for more information on potentially significant drug interactions, including clinical comments. 6

8 REAL-WORLD EXPERIENCE: TRIO NETWORK 5,6 In the TRIO Network study, data were collected directly from US specialty pharmacies through the Trio Health cloud-based disease management platform In this analysis, all patients were treated between October 214 and March 215 Of TN, noncirrhotic patients (n = 895), 62% were treated in community centers, and the remainder were treated in academic centers In contrast, 45% of TE, cirrhotic patients (n = 476) were treated in community centers, and the remainder in academic centers Baseline demographics TN, Noncirrhotic TE, Cirrhotic 8 Weeks (n = 263) a (n = 632) + RBV (n = 26) a 24 Weeks (n = 329) Age, mean (range) 57 (18-84) 6 (19-89) 58 (4-71) 61 (26-84) Male, n (%) 121 (46) 353 (56) 16 (62) 23 (7) Patient ethnicity, n (%) Black White 39 (15) 152 (58) 118 (19) 36 (48) 1 (4) 19 (73) 28 (8) 29 (64) Severe fibrosis (F3), n (%) 32 (12) 151 (24) N/A N/A HCV genotype, n (%) 1a 1b Baseline viral load, n (%) <6 million IU/mL 6 million IU/mL Prior HCV treatment, n Peg-IFN + RBV DAA 18 (69) 72 (27) 254 (97) 8 (3) 429 (68) 175 (27) 456 (72) 17 (27) 18 (69) 7 (27) 21 (81) 5 (19) N/A N/A (69) 82 (25) 283 (86) 41 (12) a 3% (n = 21) of TN, NC patients were treated with + RBV for 12 weeks, and 2% (n = 8) of TE, cirrhotic patients were treated with + RBV for 24 weeks. In the ION-1, ION-2, and ION-3 clinical trials, the addition of RBV was not shown to increase SVR12 rates observed with treatment. 1 for 8 weeks can be considered in TN, NC, GT 1 patients with a baseline viral load <6 million IU/mL. Contraindications If is used in combination with ribavirin (RBV), all contraindications, warnings and precautions, in particular pregnancy avoidance, and adverse reactions to RBV also apply. Refer to RBV prescribing information. 7

9 REAL-WORLD EXPERIENCE: TRIO NETWORK 5,6 Treatment with with or without RBV for 8, 12, or 24 weeks resulted in SVR12 rates of 92% Patients achieving SVR12 with ± RBV Patients (%) % 96% 96% 92% TN noncirrhotic TE cirrhotic 2 n = 242/254 n = 64/632 n = 25/26 n = 33/329 a 8 Weeks Baseline viral load <6 million IU/mL b + RBV Treatment Regimen and Duration b 24 Weeks for 12 weeks is recommended for TN GT 1 patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) and for TE GT 1 patients without cirrhosis. for 8 weeks can be considered in TN GT 1 patients without cirrhosis who have pre-treatment HCV RNA <6 million IU/mL. for 24 weeks is recommended for TE GT 1 patients with compensated cirrhosis (Child-Pugh A). + RBV for 12 weeks can be considered in TE GT 1 patients with compensated cirrhosis (Child-Pugh A) who are eligible for RBV. 1 Treatment discontinuation rates in the TRIO Network study TRIO Network 5,6 8 Weeks +/- RBV b b 24 Weeks TN, noncirrhotic 1% <1% N/A TE, cirrhotic N/A % b 1.5% Footnotes for both figures: a 3% (n = 9) of TN, noncirrhotic patients treated with for 8 weeks had a baseline viral load that was either unknown or 6 million IU/mL. b 3% (n = 21) of TN, noncirrhotic patients were treated with + RBV for 12 weeks, and 2% (n = 8) of TE, cirrhotic patients were treated with + RBV for 24 weeks. 5,6 In the ION-1, ION-2, and ION-3 clinical trials, the addition of RBV was not shown to increase SVR12 rates observed with treatment. 1 The overall discontinuation rate for both TRIO cohorts combined was ~1% (n = 12/1371) In the clinical trials (ION-1, ION-2, and ION-3), the discontinuation rate due to adverse events was % for patients receiving for 8 weeks, <1% for patients receiving for 12 weeks, and 1% for patients receiving for 24 weeks Warnings and Precautions Risk of Serious Symptomatic Bradycardia When Coadministered with Amiodarone: Amiodarone is not recommended for use with due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease. In patients without alternative, viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia. 8

10 REAL-WORLD EXPERIENCE Efficacy in patients who can be considered for 8 weeks of SVR12 rates in GT 1, TN, noncirrhotic patients with baseline HCV RNA <6 million IU/mL 5,6,a Patients (%) % 97% 95% 96% 8 weeks 12 weeks 2 HCV-TARGET TRIO Network in HCV GT 1: Real-world experience from HCV-TARGET and TRIO Network studies Patients achieving SVR12 with ± RBV % 95% 96% 96% 96% 92% Patients (%) Weeks + RBV 24 Weeks 2 n = 131 n = 254 n = 632 n = 627 n = 26 n = 329 HCV-TARGET TRIO TRIO b HCV-TARGET TRIO TRIO b <6 million IU/mL TN, NC TN, NC TN, NC/CC TE, CC Patients who may be considered for 8 weeks of are those with GT 1 HCV who are treatment-naïve without cirrhosis and have a baseline HCV RNA <6 million IU/mL. In ION-3, relapse rates for for 8 weeks were 2% (n = 2/123). in patients with baseline HCV RNA <6 million IU/mL and 1% (n = 9/92) in patients with baseline HCV RNA 6 million IU/mL. 1 Footnotes for both figures: a In the TRIO Network study, 3% (n = 9) of TN, noncirrhotic patients treated with for 8 weeks had a baseline viral load that was either unknown or 6 million IU/mL. b 3% (n = 21) of TN, noncirrhotic patients were treated with + RBV for 12 weeks, and 2% (n = 8) of TE, cirrhotic patients were treated with + RBV for 24 weeks. 5,6 In the ION-1 and ION-2 clinical trial, the addition of RBV was not shown to increase SVR12 rates observed with treatment. 1 Warnings and Precautions (cont.) Risk of Reduced Therapeutic Effect of Due to P-gp Inducers: Rifampin and St. John s wort are not recommended for use with as they may significantly decrease ledipasvir and sofosbuvir plasma concentrations. Related Products Not Recommended: is not recommended for use with other products containing sofosbuvir. 9

11 REAL-WORLD EXPERIENCE: SUMMARY The HCV-TARGET and TRIO Network studies were supported by Gilead Sciences, Inc. Real-world experience data were derived from patient medical records and specialty pharmacy databases. Such data are retrospective and observational in nature, and are not based on controlled clinical studies. Results from these cohorts may differ from results seen in the membership of a particular payer. High SVR12 rates were achieved regardless of duration of (8, 12, or 24 weeks) a HCV-TARGET: 95% TRIO Network: 92% Among patients who may be considered for the 8-week regimen, SVR12 rates for those who actually received it were similar to SVR12 rates for those who received for 12 weeks instead Patients who may be considered for 8 weeks of are those with GT 1 HCV who are treatmentnaive without cirrhosis and have a baseline HCV RNA <6 million IU/mL. In ION-3, relapse rates for for 8 weeks were 2% (n = 2/123) in patients with baseline HCV RNA <6 million and 1% (n = 9/92) in patients with baseline RNA 6 million IU/mL a Note: not head-to-head comparisons. Contraindications If is used in combination with ribavirin (RBV), all contraindications, warnings and precautions, in particular pregnancy avoidance, and adverse reactions to RBV also apply. Refer to RBV prescribing information. Warnings and Precautions Risk of Serious Symptomatic Bradycardia When Coadministered with Amiodarone: Amiodarone is not recommended for use with due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease. In patients without alternative, viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia. Risk of Reduced Therapeutic Effect of Due to P-gp Inducers: Rifampin and St. John s wort are not recommended for use with as they may significantly decrease ledipasvir and sofosbuvir plasma concentrations. Related Products Not Recommended: is not recommended for use with other products containing sofosbuvir. Adverse Reactions Most common ( 1%, all grades) adverse reactions were fatigue, headache and asthenia. Drug Interactions In addition to rifampin and St. John s wort, coadministration of is also not recommended with carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifapentine, and tipranavir/ritonavir. Such coadministration is expected to decrease the concentration of ledipasvir and sofosbuvir, reducing the therapeutic effect of. Coadministration of is not recommended with simeprevir due to increased concentrations of ledipasvir and simeprevir. Coadministration is also not recommended with rosuvastatin or co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate due to increased concentrations of rosuvastatin and tenofovir, respectively. Consult the full Prescribing Information for for more information on potentially significant drug interactions, including clinical comments. 1

12 References. 1. [package insert]. Foster City, CA: Gilead Sciences, Inc.; February US Food and Drug Administration. Draft guidance for industry. Chronic hepatitis C virus infection: developing direct-acting antiviral drugs for treatment. October Naggie S, et al. N Engl J Med. 215;373: Terrault N, et al. Presented at: The Liver Meeting American Association for the Study of Liver Diseases. AASLD; November 13-17, 215; San Francisco, CA. Presentation Curry M, et al. Presented at: The Liver Meeting American Association for the Study of Liver Diseases. AASLD; November 13-17, 215; San Francisco, CA. Poster Curry M, et al. Presented at: The Liver Meeting American Association for the Study of Liver Diseases. AASLD; November 13-17, 215; San Francisco, CA. Poster 118., the Logo, GILEAD, and the GILEAD Logo are trademarks of Gilead Sciences, Inc., or its related companies. 216 Gilead Sciences, Inc. All rights reserved. HVNP832 5/16

Update on Real-World Experience With HARVONI

Update on Real-World Experience With HARVONI Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were

More information

Hepatitis C Genotype 1 (GT 1) Patients in the United States (US)

Hepatitis C Genotype 1 (GT 1) Patients in the United States (US) Hepatitis C Genotype 1 (GT 1) Patients in the United States (US) INDICATION is indicated with or without ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or

More information

Patient Discussion Guide

Patient Discussion Guide Patient Discussion Guide INFORMATION AND ANSWERS TO AID YOUR COUNSELING OF PATIENTS Please click to see full Prescribing Information for HARVONI, including BOXED WARNING. CHRONIC HEPATITIS C (HEP C) GENOTYPE

More information

SOFOSBUVIR/VELPATASVIR Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR

SOFOSBUVIR/VELPATASVIR Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR EPCLUSA 43561 GUIDELINES FOR USE 1. Is the patient at least 18 years old? If yes, continue to #2. 2. Does the patient have a diagnosis of

More information

Ledipasvir-Sofosbuvir (Harvoni)

Ledipasvir-Sofosbuvir (Harvoni) HEPATITIS WEB STUDY HEPATITIS C ONLINE Ledipasvir-Sofosbuvir (Harvoni) Robert G. Gish MD Professor, Consultant, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical

More information

Highlights in the Treatment of Hepatitis C Virus From the 2016 AASLD Liver Meeting

Highlights in the Treatment of Hepatitis C Virus From the 2016 AASLD Liver Meeting December 16 Volume 12, Issue 12, Supplement 6 A SPECIAL MEETING REVIEW EDITION Highlights in the Treatment of Hepatitis C Virus From the 16 AASLD Liver Meeting A Review of Selected Presentations From the

More information

Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting 2018

Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting 2018 Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting 2018 October 11, 2018 3:24 PM ET -- More Than 50 Abstracts Across NASH, PSC, HBV and HCV Reflect

More information

Epclusa (Sofosbuvir/Velpatasvir) for HIV/HCV

Epclusa (Sofosbuvir/Velpatasvir) for HIV/HCV Mountain West AIDS Education and Training Center Epclusa (Sofosbuvir/Velpatasvir) for HIV/HCV John Scott, MD, MSc Associate Professor University of Washington Jul 28, 2016 This presentation is intended

More information

2017 UnitedHealthcare Services, Inc.

2017 UnitedHealthcare Services, Inc. UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,

More information

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Harvoni Page: 1 of 7 Last Review Date: June 19, 2015 Harvoni Description Harvoni (ledipasvir &

More information

Harvoni (sofosbuvir/ledipasvir

Harvoni (sofosbuvir/ledipasvir Market DC Override(s) Prior Authorization Quantity Limit (sofosbuvir/ledipasvir) Approval Duration Based on Genotype, Treatment status, Baseline HCV RNA status, Cirrhosis status, Transplant status, or

More information

Description of Antivirals for Hepatitis C. LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases

Description of Antivirals for Hepatitis C. LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases Description of Antivirals for Hepatitis C LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases Dwayne-David@cherokee.org Objectives Compare the different classes of direct-acting antiviral

More information

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.32 Subject: Harvoni Page: 1 of 7 Last Review Date: December 3, 2015 Harvoni Description Harvoni (ledipasvir

More information

Advances in the Treatment of Hepatitis C Virus Infection From the 2016 EASL Meeting

Advances in the Treatment of Hepatitis C Virus Infection From the 2016 EASL Meeting June 2016 Volume 12, Issue 6, Supplement 2 A SPECIAL MEETING REVIEW EDITION Advances in the Treatment of Hepatitis C Virus Infection From the 2016 EASL Meeting The Annual Meeting of the European Association

More information

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: March 18, 2016 Harvoni Description Harvoni (ledipasvir

More information

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: December 2, 2016 Harvoni Description Harvoni (ledipasvir

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy

More information

Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:

Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370: Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV

More information

RATIONALE FOR INCLUSION IN PA PROGRAM

RATIONALE FOR INCLUSION IN PA PROGRAM RATIONALE FOR INCLUSION IN PA PROGRAM Background Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with

More information

Hepatitis C Agents

Hepatitis C Agents Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 20 Last Review Date: March 16, 2018 Hepatitis C Agents Description

More information

Hepatitis C Agents

Hepatitis C Agents Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 19 Last Review Date: December 8, 2017 Hepatitis C Agents

More information

Zepatier. (elbasvir, grazoprevir) New Product Slideshow

Zepatier. (elbasvir, grazoprevir) New Product Slideshow Zepatier (elbasvir, grazoprevir) New Product Slideshow Introduction Brand name: Zepatier Generic name: Elbasvir, grazoprevir Pharmacological class: HCV NS5A inhibitor + HCV NS3/4A protease inhibitor Strength

More information

ICVH 2016 Oral Presentation: 28

ICVH 2016 Oral Presentation: 28 Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients with Genotype 1 Chronic HCV Infection in Both HCV Mono- and HIV/HCV Coinfected Patients A Luetkemeyer 1, C Cooper 2, P Kwo 3, K

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred

More information

ONE REGIMEN, ALL GENOTYPES, 8 WEEKS

ONE REGIMEN, ALL GENOTYPES, 8 WEEKS For UK healthcare professionals only INTRODUCING MAVIRET ONE REGIMEN, ALL GENOTYPES, 8 WEEKS FOR TREATMENT-NAÏVE, NON-CIRRHOTIC PATIENTS 1 Maviret is indicated for the treatment of chronic hepatitis C

More information

Sovaldi (sofosbuvir)

Sovaldi (sofosbuvir) Market DC Sovaldi (sofosbuvir) Override(s) Prior Authorization Quantity Limit Approval Duration Based on Genotype, Treatment status, Cirrhosis status, or Ribavirin Eligibility status **IN, SC, WA Medicaid

More information

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient

More information

Genotype 4, 5, or 6. Genotype. Genotype 4, 5, or 6

Genotype 4, 5, or 6. Genotype. Genotype 4, 5, or 6 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LEDIPASVIR and SOFOSBUVIR TABLETS safely and effectively. See full prescribing information for LEDIPASVIR

More information

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 7 Last Review Date: June 24, 2016 Daklinza Sovaldi Description Daklinza

More information

2017 UnitedHealthcare Services, Inc.

2017 UnitedHealthcare Services, Inc. UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2052-10 Program Prior Authorization/Medical Necessity Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 4/2015, 8/2015,

More information

PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline

PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)

More information

JOHNS HOPKINS HEALTHCARE

JOHNS HOPKINS HEALTHCARE JOHNS HOPKINS HEALTHCARE Subject: Clinical Criteria for Hepatitis C (HCV) Therapy Department: Pharmacy Lines of Business: PPMCO Policy Number: MEDS92 Effective Date: 04/15/2015 Revision Date: 08/15/2015

More information

PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline

PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni

More information

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients

5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients 5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,

More information

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.36 Subject: Daklinza Page: 1 of 8 Last Review Date: March 18, 2016 Daklinza Description Daklinza (daclatasvir)

More information

INFECTIOUS DISEASE AGENTS: HEPATITIS C - DIRECT - ACTING ANTIVIRAL

INFECTIOUS DISEASE AGENTS: HEPATITIS C - DIRECT - ACTING ANTIVIRAL Ohio Department of Medicaid Prior Authorization Form Unified PDL HEPATITIS C TREATMENT Member ID# Patient Name: DOB: Patient Address: Provider DEA: Provider NPI: Provider Name: Phone: Provider Address:

More information

Harvoni: solution to HCV

Harvoni: solution to HCV Harvoni: solution to HCV PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP Hepatitis C (HCV) Inflammation of the liver,

More information

New York State HCV Provider Webinar Series. Side Effects of Therapy

New York State HCV Provider Webinar Series. Side Effects of Therapy New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related

More information

Latest Treatment Updates for GT 2 and GT 3 Patients

Latest Treatment Updates for GT 2 and GT 3 Patients Latest Treatment Updates for GT 2 and GT 3 Patients Eric Lawitz, MD, AGAF, CPI Vice President, Scientific and Research Development The Texas Liver Institute Clinical Professor of Medicine University of

More information

Genotype 2. Genotype 3

Genotype 2. Genotype 3 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SOVALDI safely and effectively. See full prescribing information for SOVALDI. SOVALDI (sofosbuvir)

More information

and Duration HARVONI 12 weeks HARVONI 12 weeks HARVONI 24 weeks 12 weeks

and Duration HARVONI 12 weeks HARVONI 12 weeks HARVONI 24 weeks 12 weeks HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use safely and effectively. See full prescribing information for. (ledipasvir and sofosbuvir) tablets,

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hepatitis C Second Generation Antivirals Page 1 of 32 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through

More information

PEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced

PEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design

More information

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient

More information

HCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES

HCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University

More information

Hepatits C Criteria Direct Acting Antiviral Medications

Hepatits C Criteria Direct Acting Antiviral Medications Hepatits C Criteria Direct Acting Antiviral Medications Harvoni-Formulary PA required 1. Is the patient being treated for a funded condition by the Oregon Health Plan? 2. Does the member have a diagnosis

More information

REQUEST FOR PRIOR AUTHORIZATION Hepatitis C Treatments

REQUEST FOR PRIOR AUTHORIZATION Hepatitis C Treatments Fax completed form to: 866-940-7328 Prior Authorization Phone Number: 800-310-6826 IA Medicaid Member ID # Patient name Date of Birth Patient address Patient phone Provider NPI Prescriber name Phone Prescriber

More information

CENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July August

CENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July August BRAND NAME Technivie GENERIC NAME Ombitasvir/paritaprevir/ritonavir MANUFACTURER AbbVie, Inc. DATE OF APPROVAL February 27, 2017 PRODUCT LAUNCH DATE Already available on the market REVIEW TYPE Review type

More information

NEW ZEALAND DATA SHEET

NEW ZEALAND DATA SHEET NEW ZEALAND DATA SHEET 1 SOVALDI (SOFOSBUVIR 400 MG) TABLETS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Sofosbuvir 400 mg. For full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated

More information

Hepatitis C Genotypes

Hepatitis C Genotypes 9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College

More information

New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret

New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hepatitis C Second Generation Antivirals Page 1 of 30 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hepatitis C First Generation Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred

More information

HEPCVEL Tablets (Sofosbuvir 400 mg + Velpatasvir 100 mg)

HEPCVEL Tablets (Sofosbuvir 400 mg + Velpatasvir 100 mg) Published on: 3 Jul 2017 HEPCVEL Tablets (Sofosbuvir 400 mg + Velpatasvir 100 mg) Black Box Warning Risk of Hepatitis B Virus Reactivation in Patients Co-Infected with HCV And HBV Test all patients for

More information

MAVYRET (glecaprevir, pibrentasvir ) NEW PRODUCT SLIDESHOW

MAVYRET (glecaprevir, pibrentasvir ) NEW PRODUCT SLIDESHOW MAVYRET (glecaprevir, pibrentasvir ) NEW PRODUCT SLIDESHOW Introduction Brand name: Mavyret Generic name: Glecaprevir, pibrentasvir Pharmacological class: HCV NS3/4A protease inhibitor + HCV NS5A inhibitor

More information

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 4 Last Review Date: September 18, 2015 Daklinza Sovaldi Description

More information

New York State HCV Provider Webinar Series. Side Effects of Therapy and Drug-Drug Interactions

New York State HCV Provider Webinar Series. Side Effects of Therapy and Drug-Drug Interactions New York State HCV Provider Webinar Series Side Effects of Therapy and Drug-Drug Interactions Case Presentation Case 56 year-old lady with Genotype 1A Hepatitis C, Treatment-naive Noninvasive fibrosis

More information

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

2 QUALITATIVE AND QUANTITATIVE COMPOSITION AUSTRALIAN PI EPCLUSA (sofosbuvir/velpatasvir) 1 ME OF THE MEDICINE EPCLUSA (sofosbuvir/velpatasvir 400 mg/100 mg) tablets. The active substances in EPCLUSA tablets are sofosbuvir and velpatasvir. 2 QUALITATIVE

More information

Genotype 1 or weeks. Genotype 2 SOVALDI + ribavirin 12 weeks. Genotype 3 SOVALDI + ribavirin 24 weeks

Genotype 1 or weeks. Genotype 2 SOVALDI + ribavirin 12 weeks. Genotype 3 SOVALDI + ribavirin 24 weeks HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SOVALDI safely and effectively. See full prescribing information for SOVALDI. SOVALDI TM (sofosbuvir)

More information

Treatment of Hepatitis C with sofosbuvir/ledipasvir (Harvoni )

Treatment of Hepatitis C with sofosbuvir/ledipasvir (Harvoni ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak)

Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak) HEPATITIS WEB STUDY HEPATITIS C ONLINE Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir (Viekira Pak) Prepared by: Sophie Woolston, MD and David H. Spach, MD Last Updated: December 29, 2014 OMBITASVIR-PARITAPREVIR-RITONAVIR

More information

Outpatient Pharmacy Effective Date: August 15, 2014

Outpatient Pharmacy Effective Date: August 15, 2014 Therapeutic Class Code: W5Y, W5V, W0B, W0D, W0A, W0E Therapeutic Class Description: Hepatitis C Virus nucleotide analog NS5B RNA Dependent Polymerase Inhibitor, Hepatitis C Virus NS3/4A Serine Protease

More information

VIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015

VIRAL LIVER DISEASE. OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015 VIRAL LIVER DISEASE OAG Post DDW Course Westin Prince, Toronto, June 13-14, 2015 Financial Interest Disclosure (over the past 24 months) Dr. Paul Marotta Relationships related to this presentation! Research

More information

IFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster

IFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment

More information

New York State HCV Provider Webinar Series. Side Effects of Therapy and Drug-Drug Interactions

New York State HCV Provider Webinar Series. Side Effects of Therapy and Drug-Drug Interactions New York State HCV Provider Webinar Series Side Effects of Therapy and Drug-Drug Interactions Case Presentation Case 56 year-old lady with Genotype 1A Hepatitis C, Treatment-naive Noninvasive fibrosis

More information

Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1

Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 EXPEDITION-1: Study Features EXPEDITION-1 Trial Design: Open-label, single-arm,

More information

Parent drug: hours. Not reported Parent drug: 0.4 hours Major metabolite (GS ): 27 hours. ~61% to 65% bound to human plasma proteins

Parent drug: hours. Not reported Parent drug: 0.4 hours Major metabolite (GS ): 27 hours. ~61% to 65% bound to human plasma proteins Brand Name: Sovaldi Generic Name: sofosbuvir Manufacturer 3 : Gilead Sciences Inc. Drug Class 1,2 : Antiinfective, Antihepaciviral, Anti-HCV, NS5B polymerase inhibitor Uses: Labeled 1,2,3,4,5 : Chronic

More information

Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial

Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other SOFOSBUVIR/VELPATASVIR EPCLUSA TBD CUSTOMER SERVICE REPRESENTATIVE (CSR) If the member lives in Rhode Island or if the prescribing physician

More information

Program Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.

Program Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours. Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship

More information

Package Insert. Virso

Package Insert. Virso Package Insert Virso Product Summary 1. Name of the medicinal product Virso 2. Qualitative and quantitative composition Each film coated tablet contains: Sofosbuvir 400 mg Excipients 3. Pharmaceutical

More information

Why make this statement?

Why make this statement? HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed

More information

Tough Cases in HIV/HCV Coinfection

Tough Cases in HIV/HCV Coinfection NORTHWEST AIDS EDUCATION AND TRAINING CENTER Tough Cases in HIV/HCV Coinfection John Scott, MD, MSc Assistant Professor University of Washington Presentation prepared by: J Scott Last Updated: Jun 5, 2014

More information

The Dawn of a New Era: Hepatitis C

The Dawn of a New Era: Hepatitis C The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should

More information

Sovaldi (sofosbuvir) with PegIntron (peginterferon alfa-2b) and Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin)

Sovaldi (sofosbuvir) with PegIntron (peginterferon alfa-2b) and Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.24 Subject: Sovaldi PegIntron Ribavirin Page: 1 of 6 Last Review Date: November 30, 2018 Sovaldi PegIntron

More information

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,

More information

AmeriHealth Caritas Iowa Request for Prior Authorization Hepatitis C Treatments

AmeriHealth Caritas Iowa Request for Prior Authorization Hepatitis C Treatments Form applies to IA Health Link and hawk-i plans. Please print accuracy is important. Fax completed form to 1-855-825-2714. Provider Help Desk: 1-855-328-1612. AmeriHealth Caritas Iowa member ID #: Patient

More information

SOLAR-1 (Cohorts A and B)

SOLAR-1 (Cohorts A and B) Phase 2 Treatment Naïve and Treatment Experienced Ledipasvir-Sofosbuvir + RBV in HCV GT 1,4 and Advanced Liver Disease SOLAR-1 (Cohorts A and B) Charlton M, al. Gastroenterology. 2015; 149:649-59. Ledipasvir-Sofosbuvir

More information

Antiviral treatment in HCV cirrhotic patients on waiting list

Antiviral treatment in HCV cirrhotic patients on waiting list Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory

More information

HEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation

HEPATITIS WEB STUDY. Treatment of Hepatitis C following Liver Transplantation HEPATITIS WEB STUDY Treatment of Hepatitis C following Liver Transplantation Terry D. Box, MD Associate Professor of Medicine Division of Gastroenterology/Hepatology University of Utah Health Sciences

More information

Future strategies with new DAAs

Future strategies with new DAAs Future strategies with new DAAs Ola Weiland professor New direct antiviral drugs Case no 1 male with genotype 2b Male with gt 2b chronic HCV Male with gt 2b relapse afer peg-ifn + RBV during 24 weeks

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked

More information

Initial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona

Initial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives

More information

Sovaldi (sofosbuvir) with Pegasys (peginterferon alfa-2a) and Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin)

Sovaldi (sofosbuvir) with Pegasys (peginterferon alfa-2a) and Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.25 Subject: Sovaldi Pegasys Ribavirin Page: 1 of 6 Last Review Date: December 8, 2017 Sovaldi Pegasys

More information

NEW ZEALAND DATA SHEET. HARVONI tablets are orange diamond shaped debossed with GSI on one side and the number 7985 on the other side.

NEW ZEALAND DATA SHEET. HARVONI tablets are orange diamond shaped debossed with GSI on one side and the number 7985 on the other side. NEW ZEALAND DATA SHEET 1 HARVONI (LEDIPASVIR 90 MG, SOFOSBUVIR 400 MG) TABLETS) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Ledipasvir 90 mg and sofosbuvir 400 mg) For full list of excipients, see section

More information

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA

Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on

More information

Subject: Hepatitis C Drug Therapy

Subject: Hepatitis C Drug Therapy 09-J0000-53 Original Effective Date: 01/01/06 Reviewed: 07/11/18 Revised: 11/15/18 Subject: Hepatitis C Drug Therapy THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION

More information

Australasian Professional Society on Alcohol and other Drugs, Annual Conference 2016 Sydney Australia

Australasian Professional Society on Alcohol and other Drugs, Annual Conference 2016 Sydney Australia Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: Analysis of Phase 3 ION trials J Grebely

More information

Hepatitis C in Dr. Michael Bays D.O.

Hepatitis C in Dr. Michael Bays D.O. Hepatitis C in 2015 Dr. Michael Bays D.O. HCV Virology Member of the Flavivirus family (Yellow Fever, Dengue) Hepacivirus genus Enveloped, positive, singlestranded RNA virus 9.6 Kb genome encodes a single

More information

Sofosbuvir (Sovaldi) Drug Summary. Class and Mechanism. Table of Contents

Sofosbuvir (Sovaldi) Drug Summary. Class and Mechanism. Table of Contents Hepatitis C Online PDF created July 12, 2018, 1:44 pm Sofosbuvir (Sovaldi) Table of Contents Sofosbuvir Sovaldi Editor's Summary Drug Summary Class and Mechanism Manufacturer for United States Cost and

More information

Update in the Management of Hepatitis C: What Does the Future Hold

Update in the Management of Hepatitis C: What Does the Future Hold Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana

More information

WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV

WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV There are recent changes to the Prescribing Information (PI) and Patient Information (PPI) for ZEPATIER (elbasvir and grazoprevir) 50 mg/100 mg tablets. The class labeling revisions now included in the

More information

Cost effectiveness of sofosbuvir and ledipasvir (Harvoni ) in combination with other medicinal products for the treatment of hepatitis C infection

Cost effectiveness of sofosbuvir and ledipasvir (Harvoni ) in combination with other medicinal products for the treatment of hepatitis C infection Cost effectiveness of sofosbuvir and ledipasvir (Harvoni ) in combination with other medicinal products for the treatment of hepatitis C infection The NCPE has issued a recommendation regarding the cost

More information

A dosage recommendation cannot be made for patients with severe renal impairment or end stage renal disease. (2.3)

A dosage recommendation cannot be made for patients with severe renal impairment or end stage renal disease. (2.3) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SOFOSBUVIR and VELPATASVIR TABLETS safely and effectively. See full prescribing information for SOFOSBUVIR

More information

Selected Properties of Daclatasvir

Selected Properties of Daclatasvir Selected Properties of Daclatasvir Other names Manufacturer Pharmacology / Mechanism of Action Activity Resistance Genotypic Daklinza, BMS-790052 Bristol-Myers Squibb Daclatasvir is a highly potent and

More information

Topic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015

Topic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014

More information

Learning Objective. After completing this educational activity, participants should be able to:

Learning Objective. After completing this educational activity, participants should be able to: Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential

More information

Pharmacy Medical Necessity Guidelines: Hepatitis C Virus

Pharmacy Medical Necessity Guidelines: Hepatitis C Virus Pharmacy Medical Necessity Guidelines: Hepatitis C Virus Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX)

More information

Pegylated Interferon Agents for Hepatitis C

Pegylated Interferon Agents for Hepatitis C Applicable X X X X X X X Pegylated Interferon Agents for Hepatitis C Override(s) Prior Authorization Quantity Limit Initial for Monotherapy or Combination with Ribavirin based on Genotype, Status, or Co-Infection

More information